Coronavirus disease 2019 (COVID-19) is a major public health issue around the world and new data about its etiological agent, the severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2), are urgently necessary, also translating the scientific knowledge acquired on its more similar predecessors, the severe-acute-respiratory-syndrome-coronavirus-1 (SARS-CoV-1) and the Middle-East-respiratory-syndrome-related-coronavirus (MERS-CoV), the coronaviruses responsible for SARS and MERS, respectively. The discovery of MERS-CoV dates back to 2012, when it was initially identified in Saudi Arabia [@b0005]. Also known as «camel flu», MERS is a potentially severe respiratory illness with a lethality rate of around 34% and today is still circulating among the population, in particular of the Arabian Peninsula, without a fully protective vaccine available [@b0010]. Subsequent studies on MERS-CoV have highlighted that the virus enters the host cell through cluster of differentiation 26 (CD26), alias dipeptidyl peptidase-4 (DPP-4) receptor [@b0015]. This «moonlighting protein»\* is highly conserved across species, datum which explains the possible infection in camels and bats, and it is mainly expressed in the human bronchial epithelium and kidneys, as well as memory and naїve T lymphocytes [@b0020]. In particular, it has been found overexpressed in T-helper type 1 (T~h~1) rather than T-helper type 2 (T~h~2) cells, and its expression in T~h~1 increases with aging [@b0025], [@b0030], [@b0035]. As well known, naїve T-helper cells (T~h~0) can detect novel pathogens never encountered before, as is the current case of SARS-CoV-2. Depending on the infectious agent, T~h~0 then polarize the immune response into T~h~1, the default response in immunocompetent subjects to intracellular or phagocytosable pathogens (*e.g.* viruses, bacteria, protozoa, fungi) and mediated by macrophages and T-cytotoxic (T~c~) cells, or into T~h~2, classically directed against extracellular non-phagocytosable pathogens (*e.g.* helminths), whose main effectors are eosinophils, basophils, mastocytes and B cells [@b0040]. During our researches on COVID-19, for many clinic-laboratory aspects including lymphopenia quite similar to MERS, we have disclosed that the immune system mounts a T~h~2 response against SARS-CoV-2 in patients requiring intensive care, rather than a T~h~1 response, which would keep the infection under control by means of macrophages and T~c~ cells [@b0045]. In addition, for the first time in worldwide literature, we have provide evidence that a life-threatening escalation from T~h~2 immune response to type 3 hypersensitivity (*immune complex disease*) in COVID-19 vasculitis takes place, and that the inflamed smooth muscle cells of blood vessels concur to the «cytokine storm» via interleukin-6 [@b0050], [@b0055]. In the last four months, two independent bioinformatics research groups have reported that the spike glycoprotein of SARS-CoV-2 not only binds the angiotensin converting enzyme 2 (ACE2) receptors [@b0060], the same entry mechanism exploited by SARS-CoV-1, but potentially interacts also with CD26/DPP-4, a proposed pivotal event for hijacking and virulence, exactly how MERS-CoV works [@b0065], [@b0070]. Faced with this scenario, it is possible that T~h~1 and T~c~ lymphocytes are the immune cells most affected by the viral load, especially in the elderly, and that the immune system is forced to mount a T~h~2 response, the only one still mountable, in the attempt to counteract the pathogen by the action of T~h~2 effectors ([Fig. 1](#f0005){ref-type="fig"} ). However, in this way, the symptomatic patient experiences all the negative effects of the T~h~2 response, which can seriously aggravate the clinical picture.Fig. 1During the ongoing SARS-CoV-2 outbreak in the Italian province of Modena, COVID-19 autopsies have been limited for biosafety reasons. However, three male patients, two Italian and one non-Italian, 67, 49 and 44 years old respectively, have been submitted to minimally invasive autopsies: in these cases, the white pulp of the spleen appears markedly reduced (A, hematoxylin and eosin, 4X objective), with CD8-positive T~c~ almost disappeared (B, clone SP57, 10X objective) and scanty CD4-positive T~h~ still present (C, clone SP35, 10X objective), likely T~h~2 elements since surrounded by scattered CD138-positive plasma cells (D, clone B-A38, 10X objective) \[immunohistochemistry chromogen: 3,3′-diaminobenzidine\].
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A «moonlighting protein» is a protein able to perform more than one biological function: besides to be a lymphocyte activation antigen, CD26/DPP-4 increases glucose levels favoring incretins degradation and, for this reason, it is the molecular target of a specific class of oral hypoglycemics, the DPP-4 inhibitors.
